In coronavirus disease 2019 (COVID‐19), higher morbidity and mortality are associated with
age, male gender, and comorbidities, such as chronic lung diseases, cardiovascular …

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the extracellular
matrix (ECM) of the pulmonary arteries with increased collagen deposition, cross-linkage of …

A practical guide to working with the principles of polyvagal theory beyond the therapy
session. Deb Dana is the foremost translator of polyvagal theory into clinical practice. Here …

Pulmonary hypertension (PH), previously defined as a mean pulmonary artery pressure of
greater than 25 mm Hg, has recently been redefined by the Sixth World Symposium on …

The World Symposium on Pulmonary Hypertension (WSPH) was organized by the World
Health Organization in 1973 in response to an increase in pulmonary arterial hypertension …

Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right
ventricular dysfunction and exercise limitation and progresses to death. New findings from …

Heart failure (HF) is a global pandemic with a poor prognosis after hospitalization. Despite
HF syndrome complexities, evidence of significant sympathetic overactivity in the …

Abstract Background World Health Organization (WHO) group 1 pulmonary arterial
hypertension (PAH) is a progressive, debilitating disease. Previous observational studies …

Since the outbreak of the COVID-19 pandemic, races across academia and industry have
been initiated to identify and develop disease modifying or preventative therapeutic …

Background Pulmonary hypertension (PH), characterized by elevated pulmonary pressure
and right heart failure, is a systemic disease involving inappropriate sympathetic activation …